Mini-dose Esketamine-dexmedetomidine Supplemented Analgesia and Long-term Outcomes
Status:
Active, not recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Chronic postsurgical pain (CPSP) refers to pain that occurs or increases after surgery and
lasts longer than 3 months. Severe postoperative acute pain is one of major risk factors of
CPSP. Spine surgery brings severe postoperative pain due to large trauma and long duration.
Ketamine and esketamine are N-methyl-D-aspartate receptor antagonists; they have
anti-hyperalgesic effects and may reduce CPSP. Dexmedetomidine is a alpha 2-adrenoceptor
agonist with sedative, anxiolytic and analgesic effect; it is frequently used as a adjuvant
to postoperative analgesia. In a previous trial, 200 patients following scoliosis correction
surgery were randomzied to receive opioid analgsia supplemented with either mini-dose
esketamine-dexmedetomidine combination or placebo. The results showed that
esketamine-dexmedetomidine supplement analgesia significantly improved analgesia and sleep
quality after surgery. This study is designed to test the hypothesis that mini-dose
esketamine-dexmedetomidine supplemented analgesia may reduce CPSP at 2 years after scoliosis
correction surgery.